High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine. These are the findings of a study published today in The New England Journal of Medicine, led by researchers at Karolinska Institutet and Danderyd Hospital in Sweden.